EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Reference library IUPHAR/BPS and ICH sources Peer-reviewed reviews and human studies Schematics and calculations

Receptors and signaling pathways

How a cell receives a chemical signal: the receptor families that bind it, the terms pharmacologists use to describe binding and response, nine pathways that carry the signal inward, the liver sensors that respond to foreign compounds, and why a concentration that works in a dish may never occur in a person.

≈800G protein-coupled receptors in the human genome, about half of them sensory
58human receptor tyrosine kinases, in 20 subfamilies
48human nuclear receptors, the ligand-activated transcription factors
27 nMKi of hyperforin, from St John's wort, for the pregnane X receptor (PXR), in vitro binding

Alexander SPH, et al. Br J Pharmacol 2025;182(Suppl 1):S24–S151 and S259–S306; Lemmon MA, Schlessinger J. Cell 2010;141:1117–1134; Frigo DE, et al. Essays Biochem 2021;65:847–856; Moore LB, et al. Proc Natl Acad Sci USA 2000;97:7500–7502.

Status. Education, not medical advice. This page explains textbook physiology and pharmacology; it gives no dosing advice and makes no claim that any supplement treats or prevents a disease. The two computed figures are educational calculations, not measurements. EUTECNIQ is in formation and has no laboratory or studies running.

Related: ADME, PK and PBPK · Bioactive compounds · Bioavailability design

Receptors

Five receptor types turn a bound chemical signal into a response

A receptor is a protein that binds a signaling molecule and changes shape, so that binding becomes a response. Four types sit in the cell membrane and read signals from outside; nuclear receptors sit inside the cell and bind DNA.

Each receptor type turns binding into a different first event: a G protein, an open pore, a kinase, a bound JAK or a gene switched onSchematic, not to scale
Five receptor types drawn across the plasma membrane: a G protein-coupled receptor with seven transmembrane helices and a G protein; a ligand-gated ion channel; a receptor tyrosine kinase dimer; a cytokine receptor dimer with JAKs; and a nuclear receptor dimer bound to DNA in the nucleusOutside the cellCytoplasmTransmembrane helix TM1Transmembrane helix TM2Transmembrane helix TM3Transmembrane helix TM4Transmembrane helix TM5Transmembrane helix TM6Transmembrane helix TM7NCAgonist in the binding pocketGαβγ1. G protein-coupledreceptors7 transmembrane helices;about 800 in humans; activateGα·βγOne subunit (two of five shown)One subunit (two of five shown)Transmitter bound to the extracellular domainions2. Ligand-gated ionchannelsBinding opens a pore withinmilliseconds; nACh, 5-HT3,GABAA​, glycine: pentamersIntracellular tyrosine kinase domainPIntracellular tyrosine kinase domainPGrowth factor bridging two receptors3. Receptor tyrosinekinases1 transmembrane helix; ligandinduces dimerization;trans-autophosphorylation; 58human RTKsPPCytokineJAK4. Cytokine receptorsAssociated JAKsphosphorylate the receptor,which recruits STATsLipophilic ligandNucleusHormone response element in DNAnucleus5. Nuclear receptorsInside the cell;ligand-activated transcriptionfactors; 48 in humansFive receptor types, one per row, each drawn across the plasma membrane with its defining structureTransmembrane helix TM1Transmembrane helix TM2Transmembrane helix TM3Transmembrane helix TM4Transmembrane helix TM5Transmembrane helix TM6Transmembrane helix TM7NCAgonist in the binding pocketGαβγ1. G protein-coupledreceptors7 transmembrane helices;about 800 in humans; activateGα·βγOne subunit (two of five shown)One subunit (two of five shown)Transmitter bound to the extracellular domainions2. Ligand-gated ionchannelsBinding opens a pore withinmilliseconds; nACh, 5-HT3,GABAA​, glycine: pentamersIntracellular tyrosine kinase domainPIntracellular tyrosine kinase domainPGrowth factor bridging two receptors3. Receptor tyrosinekinases1 transmembrane helix; ligandinduces dimerization;trans-autophosphorylation; 58human RTKsPPCytokineJAK4. Cytokine receptorsAssociated JAKsphosphorylate the receptor,which recruits STATsLipophilic ligandNucleusHormone response element in DNAnucleus5. Nuclear receptorsInside the cell;ligand-activated transcriptionfactors; 48 in humans
Structures as described by the IUPHAR/BPS Concise Guide to PHARMACOLOGY (GPCRs and catalytic receptors 2025/26; ion channels 2023/24; nuclear hormone receptors 2025/26), Lemmon and Schlessinger 2010 and Frigo et al. 2021. Ion channel drawn as two of its five subunits; ligands, G protein and DNA are symbols.

Speed and reach differ: an ion channel opens on a millisecond time scale, while a nuclear receptor acts by changing which genes are transcribed.

Explanation, details and sources
The five receptor types: structure, first signaling event and human member counts
Receptor typeStructureWhat binding doesHuman members, as the source states
G protein-coupled receptors (GPCRs)One chain with an extracellular N-terminus, seven transmembrane helices (TM1–TM7) joined by three extracellular and three intracellular loops, and an intracellular C-terminusThe receptor acts as a guanine nucleotide exchange factor: Gα releases GDP, binds GTP and separates from Gβγ; both parts then regulate effectorsAbout 800, about half sensory; about 350 non-sensory receptors are the targets of most drugs in clinical use
Ligand-gated ion channelsnACh, 5-HT3, GABAA and glycine receptors (and the zinc-activated channel) are pentamers, the Cys-loop receptors; ionotropic glutamate receptors are tetramers; P2X receptors are trimersA transmitter binds the orthosteric site and the pore opens; ions flow down their electrochemical gradient, giving fast synaptic transmission on a millisecond time scaleGrouped by family in the Concise Guide; no single total given
Receptor tyrosine kinases (RTKs)Extracellular ligand-binding domain, one transmembrane helix, intracellular tyrosine kinase domainThe ligand induces dimerization (insulin and IGF1 receptors are already disulfide-linked dimers); the kinases phosphorylate each other in trans, creating docking sites for PLCγ, MAP kinase and PI3K pathways58 RTKs in 20 subfamilies
Cytokine receptors (with JAKs)Type I receptors carry a WSXWS motif in the cytokine receptor homology domain; type II receptors lack itBinding recruits intracellular partners; for most cytokine receptors these are Janus kinases (JAKs), whose tyrosine kinase activity phosphorylates the receptor and recruits STATs4 JAKs (JAK1, JAK2, JAK3, TYK2) and 7 STATs; more than 50 cytokines and growth factors signal this way
Nuclear receptorsDomains A/B (AF-1), C (DNA-binding, two zinc fingers), D (hinge with nuclear localization signal), E (ligand-binding, AF-2) and FMost ligands are small lipophilic compounds that diffuse across the plasma membrane; the receptor binds hormone response elements in DNA as a homodimer, heterodimer or monomer and recruits coregulators48

Alexander SPH, et al. The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors. Br J Pharmacol 2025;182(Suppl 1):S24–S151; Syrovatkina V, et al. J Mol Biol 2016;428:3850–3868; Alexander SPH, et al. Concise Guide 2023/24: Ion channels. Br J Pharmacol 2023;180(Suppl 2):S145–S222; Lemmon MA, Schlessinger J. Cell 2010;141:1117–1134; Alexander SPH, et al. Concise Guide 2025/26: Catalytic receptors. Br J Pharmacol 2025;182(Suppl 1):S259–S306; Hu X, et al. Signal Transduct Target Ther 2021;6:402; Frigo DE, Bondesson M, Williams C. Essays Biochem 2021;65:847–856; Alexander SPH, et al. Concise Guide 2025/26: Nuclear hormone receptors. Br J Pharmacol 2025;182(Suppl 1):S242–S258.

Gα proteins form four families: Gαs (stimulates adenylyl cyclase), Gαi (inhibits some adenylyl cyclase isoforms), Gαq (activates phospholipase Cβ) and Gα12. Humans have 5 Gβ and 12 Gγ genes (Syrovatkina et al. 2016). The catalytic-receptor superfamily also includes guanylyl cyclase receptors, receptor serine/threonine kinases such as the TGF-β and BMP receptors, receptor tyrosine phosphatases and integrins (Concise Guide 2025/26).

Class A holds 719 of about 800 human GPCRs, and 435 of those are sensory receptorsPublished counts
Human G protein-coupled receptors by class: class A has 719 members, 435 of them sensory; classes B, C, adhesion and frizzled have 15, 23, 33 and 11receptors with known ligandsorphanssensoryClass A (rhodopsin)Class A (rhodopsin): 197 receptors with known ligandsClass A (rhodopsin): 87 orphansClass A (rhodopsin): 435 sensory719sensory: olfactory 390, opsins 10, taste 2 30, vomeronasal 1 5Class B (secretin)Class B (secretin): 15 receptors with known ligands15Class C (glutamate)Class C (glutamate): 12 receptors with known ligandsClass C (glutamate): 8 orphansClass C (glutamate): 3 sensory23AdhesionAdhesion: 33 orphans33FrizzledFrizzled: 11 receptors with known ligands11Total about 800 GPCRs; about half sensory (≈400 olfactory, 33 taste, 10 light, 5 pheromone)Human G protein-coupled receptors by class: class A has 719 members, 435 of them sensory; classes B, C, adhesion and frizzled have 15, 23, 33 and 11receptors with known ligandsorphanssensoryClass A (rhodopsin)Class A (rhodopsin): 197 receptors with known ligandsClass A (rhodopsin): 87 orphansClass A (rhodopsin): 435 sensory719sensory: olfactory 390, opsins10, taste 2 30, vomeronasal 1 5Class B (secretin)Class B (secretin): 15 receptors with known ligands15Class C (glutamate)Class C (glutamate): 12 receptors with known ligandsClass C (glutamate): 8 orphansClass C (glutamate): 3 sensory23AdhesionAdhesion: 33 orphans33FrizzledFrizzled: 11 receptors with known ligands11Total about 800 GPCRs; about half sensory (≈400 olfactory,33 taste, 10 light, 5 pheromone)
Alexander SPH, et al. Br J Pharmacol 2025;182(Suppl 1):S24–S151, GPCR overview table. Sensory class A: olfactory 390, opsins 10, taste 2 receptors 30, vomeronasal 1 receptors 5; class C: taste 1 receptors 3.
Show data: human GPCRs by class
Human G protein-coupled receptors by class, from the Concise Guide to PHARMACOLOGY 2025/26
ClassKnown ligandsOrphansSensoryTotal
Class A (rhodopsin)19787435719
Class B (secretin)15——15
Class C (glutamate)128323
Adhesion033—33
Frizzled110—11

The guide's text gives the rounded totals: about 800 GPCRs, about 400 olfactory, 33 taste, 10 light and 5 pheromone receptors, and about 350 non-sensory receptors. Sensory class A total (435) summed on this page from the table.

Every nuclear receptor except DAX1 and SHP shares the same domain order, with DNA binding in the middle and ligand binding near the C-terminusSchematic, domain lengths not to scale
Nuclear receptor domain map from the N-terminus: A/B with AF-1, C with the DNA-binding zinc fingers, D hinge, E ligand-binding domain with AF-2, and FNCA/B: N-terminal domain, AF-1A/BN-terminal domain,AF-1C: DNA-binding domain, two zinc fingersCDNA-binding domain,two zinc fingersD: hinge, nuclear localization signalDhinge, nuclearlocalization signalE: ligand-binding domain, AF-2Eligand-binding domain, AF-2F: variable C-terminal, in some receptorsFvariableC-terminal,in somereceptorsNuclear receptor domain map from the N-terminus: A/B with AF-1, C with the DNA-binding zinc fingers, D hinge, E ligand-binding domain with AF-2, and FNCA/B: N-terminal domain, AF-1A/BC: DNA-binding domain, two zinc fingersCD: hinge, nuclear localization signalDE: ligand-binding domain, AF-2EF: variable C-terminal, in some receptorsFA/B: N-terminal domain, AF-1C: DNA-binding domain, two zinc fingersD: hinge, nuclear localization signalE: ligand-binding domain, AF-2F: variable C-terminal, in some receptors
Frigo DE, Bondesson M, Williams C. Essays Biochem 2021;65:847–856, Figure 2 and text.
Pharmacology

Affinity, efficacy and potency are different properties

Affinity says how tightly a compound binds; efficacy says what the bound receptor then does; potency says how much compound is needed for a given effect. A compound can bind tightly and do nothing, which is how a competitive antagonist works. The equation that links concentration to effect is the Hill equation, explained on the ADME and PK page.

Definitions of basic receptor pharmacology terms with their sources
TermDefinitionSource
AffinityThe ability of a drug to bind a receptor; numerically 1/KD, where KD, the equilibrium dissociation constant, is the concentration that occupies 50% of the receptorsBerg and Clarke 2018
Intrinsic efficacyThe effect a drug has on receptor activity once bound; a constant for each drug–receptor pair that cannot be measured directly, so it is expressed relative to a reference drugBerg and Clarke 2018
PotencyThe amount of drug needed to produce an effect of a given size, usually given as EC50 or ED50; affinity is one of the factors that set itSalahudeen and Nishtala 2017
AgonistActivates the receptor to produce a response; some agonists reach the maximal response without occupying all receptorsSalahudeen and Nishtala 2017
Partial agonistBinds and activates but cannot produce the full response; at high concentration it can reduce the effect of a full agonist to its own maximumSalahudeen and Nishtala 2017
AntagonistBinds without producing a response and blocks the agonist. A competitive antagonist binds reversibly at the agonist's site and shifts the concentration–response curve to the right without lowering the maximumSalahudeen and Nishtala 2017; Wyllie and Chen 2007
Inverse agonistHas negative intrinsic efficacy: it lowers the activity a receptor shows without any ligand (constitutive activity). Many clinically used drugs first classed as antagonists show inverse agonist properties in suitable test systemsBerg and Clarke 2018
Allosteric modulatorBinds a site topographically distinct from the orthosteric (agonist) site and changes the receptor's affinity for, or response to, the orthosteric ligand. A cooperativity factor α > 1 is positive (potentiation, PAM), 0 < α < 1 negative (NAM), α = 1 neutralConn, Christopoulos and Lindsley 2009

Berg KA, Clarke WP. Int J Neuropsychopharmacol 2018;21:962–977; Salahudeen MS, Nishtala PS. Saudi Pharm J 2017;25:165–175; Wyllie DJA, Chen PE. Br J Pharmacol 2007;150:541–551; Conn PJ, Christopoulos A, Lindsley CW. Nat Rev Drug Discov 2009;8:41–54.

Agonists, antagonists and inverse agonists sit on one scale of intrinsic efficacySchematic of definitions
Ligands placed on a scale of intrinsic efficacy: inverse agonist below zero, neutral antagonist at zero, partial agonist between zero and one, full agonist at oneIntrinsic efficacy, relative to a full agonist01Inverse agonist: lowers basal (constitutive) activity: negative efficacyInverse agonistlowers basal (constitutive)activity: negative efficacyNeutral antagonist: binds without changing activity; blocks other ligandsNeutral antagonistbinds without changing activity;blocks other ligandsPartial agonist: activates, but cannot reach the full responsePartial agonistactivates, but cannot reach thefull responseFull agonist: can produce the maximal responseFull agonistcan produce the maximalresponseLigands placed on a vertical scale of intrinsic efficacyintrinsic efficacy01Inverse agonistlowers basal (constitutive) activity: negativeefficacyNeutral antagonistbinds without changing activity; blocks otherligandsPartial agonistactivates, but cannot reach the full responseFull agonistcan produce the maximal response
Positions show sign and order only; partial agonists can lie anywhere between 0 and 1. Berg and Clarke 2018: in two-state models, ligands with higher affinity for the active state act as agonists, those with higher affinity for the inactive state as inverse agonists, and those with equal affinity as neutral antagonists.

For a competitive antagonist B, Wyllie and Chen write the Schild equation in normalized concentrations, r = 1 + cB, where cB = [B]/KB and the dose ratio r is the factor by which agonist concentration must rise to restore the response seen without antagonist. The equation contains no term for the agonist or its efficacy.

A competitive antagonist moves the curve right in parallel by r = 1 + [B]/KB; the Schild plot of log(r − 1) is a line of slope 1Educational calculation
Calculated agonist concentration-response curves shifted right in parallel by a competitive antagonist at 0, 1, 10 and 100 times its K_B, with the same maximum; and the Schild plot of log(r − 1) against log([B]/K_B), a straight line of slope 100.250.50.751Response, E/Emax​0.010.11101001000104​105​Agonist concentration, [A]/EC50​[B] = 0[B] = K_{B}[B] = 10 K_{B}[B] = 100 K_{B}[B] = 0: EC50 shifted 1-fold (r = 1 + [B]/KB)[B] = K_{B}: EC50 shifted 2-fold (r = 1 + [B]/KB)[B] = 10 K_{B}: EC50 shifted 11-fold (r = 1 + [B]/KB)[B] = 100 K_{B}: EC50 shifted 101-fold (r = 1 + [B]/KB)[B] = 0[B] = KB​, r = 2[B] = 10 KB​, r = 11[B] = 100 KB​, r = 101012log10​(r − 1)012log10​([B]/KB​)[B] = K_{B}: r − 1 = 1[B] = 10 K_{B}: r − 1 = 10[B] = 100 K_{B}: r − 1 = 100slope = 1[B] = KB​: r = 2, log(r − 1) = 0Calculated agonist concentration-response curves shifted right in parallel by a competitive antagonist at 0, 1, 10 and 100 times its K_B, with the same maximum; and the Schild plot of log(r − 1) against log([B]/K_B), a straight line of slope 100.250.50.751Response, E/Emax​0.010.11101001000104​105​Agonist concentration, [A]/EC50​[B] = 0[B] = K_{B}[B] = 10 K_{B}[B] = 100 K_{B}[B] = 0: EC50 shifted 1-fold (r = 1 + [B]/KB)[B] = K_{B}: EC50 shifted 2-fold (r = 1 + [B]/KB)[B] = 10 K_{B}: EC50 shifted 11-fold (r = 1 + [B]/KB)[B] = 100 K_{B}: EC50 shifted 101-fold (r = 1 + [B]/KB)[B] = 0[B] = KB​, r = 2[B] = 10 KB​, r = 11[B] = 100 KB​, r = 101012log10​(r − 1)012log10​([B]/KB​)[B] = K_{B}: r − 1 = 1[B] = 10 K_{B}: r − 1 = 10[B] = 100 K_{B}: r − 1 = 100slope = 1[B] = KB​: r = 2, log(r − 1) = 0
Calculated from the Schild equation, r = 1 + [B]/KB, as stated by Wyllie DJA, Chen PE. Br J Pharmacol 2007;150:541–551, applied to a Hill curve with coefficient 1: E/Emax = x/(x + r), x = [A]/EC50. Concentrations are normalized (EC50 = KB = 1), so no compound-specific parameters are used. An educational calculation, not a measurement or a prediction for any product.
Show data: dose ratios in the calculation
Antagonist concentration, dose ratio and shifted EC50 in the Schild calculation
[B]/KBDose ratio r = 1 + [B]/KBApparent EC50 (multiples of the control EC50)log10(r − 1)
011—
1220
1011111
1001011012

Wyllie and Chen's tests for competitive antagonism are parallel rightward shifts with no fall in the maximum response. A log–log plot of r − 1 against antagonist concentration then gives a straight line of slope 1, and only then does its intercept estimate KB. pA2, the negative log of the antagonist concentration that gives r = 2, equals −log10 KB only when the slope is 1.

Pathways

Nine pathways carry a receptor signal to its target

Behind each receptor is a chain of enzymes, small messenger molecules and transcription factors. Arrows below mean “activates” and flat-ended lines mean “inhibits”. Each drawing shows the core steps the cited review describes, not every branch.

Second messengers: cAMP, IP3, DAG, Ca2+ and cGMP carry a membrane signal into the cellSchematic, simplified
Three second-messenger pathways: cAMP and PKA; Gq, PLC-beta, IP3, DAG, calcium and PKC; nitric oxide and cGMP. Arrows activate; flat-ended lines inhibitcAMP and protein kinase ANucleusHormone or transmitterGPCRGαs·GTPGαi·GTP (otherGPCRs)Adenylyl cyclasecAMP (from ATP)PKA: cAMP binds Rsubunits, frees CsubunitsEPAC; cyclicnucleotide-gatedchannelsCREB phosphorylated at Ser133Genes with CREs (TGACGTCA)Gq, PLCβ, IP₃, DAG, Ca²⁺ and PKCbinds C1Hormone or transmitterGPCRGαq·GTPPLCβ cleaves PIP₂IP₃ (soluble)DAG (stays inmembrane)IP₃ receptorchannel on the ERCa²⁺ releasedfrom the ERPKC(conventional,novel)Phosphorylated substratesNitric oxide and cGMPEndothelial cellSmooth muscle celldiffusesCa²⁺·calmodulinL-arginine + O₂eNOS (NOS3), NADPHNO + L-citrullineSoluble guanylyl cyclasecGMP (from GTP)PKG(cGMP-dependentprotein kinase)PDE5 hydrolyzescGMPSmooth muscle relaxationThree second-messenger pathways: cAMP and PKA; Gq, PLC-beta, IP3, DAG, calcium and PKC; nitric oxide and cGMP. Arrows activate; flat-ended lines inhibitcAMP and protein kinase ANucleusHormone or transmitterGPCRGαs·GTPGαi·GTP (other GPCRs)Adenylyl cyclasecAMP (from ATP)PKA: cAMP binds Rsubunits, frees CsubunitsEPAC; cyclicnucleotide-gatedchannelsCREB phosphorylated at Ser133Genes with CREs (TGACGTCA)Gq, PLCβ, IP₃, DAG, Ca²⁺ and PKCbinds C1Hormone or transmitterGPCRGαq·GTPPLCβ cleaves PIP₂IP₃ (soluble)DAG (stays inmembrane)IP₃ receptor channel onthe ERCa²⁺ released from theERPKC (conventional,novel)Phosphorylated substratesNitric oxide and cGMPEndothelial cellSmooth muscle celldiffusesCa²⁺·calmodulinL-arginine + O₂eNOS (NOS3), NADPHNO + L-citrullineSoluble guanylyl cyclasecGMP (from GTP)PKG (cGMP-dependentprotein kinase)PDE5 hydrolyzes cGMPSmooth muscle relaxation
Syrovatkina et al. 2016; Altarejos JY, Montminy M. Nat Rev Mol Cell Biol 2011;12:141–151; Taylor SS, et al. Biochim Biophys Acta 2013;1834:1271–1278; Newton AC. Crit Rev Biochem Mol Biol 2018;53:208–230; Cyr AR, et al. Crit Care Clin 2020;36:307–321; Francis SH, Busch JL, Corbin JD. Pharmacol Rev 2010;62:525–563.
Text version: cAMP/PKA, Gq/PLC/PKC and NO/cGMP
Steps of three second-messenger pathways
PathwayStepsSource
cAMP / PKAA GPCR activates Gαs, which stimulates adenylyl cyclase to make cAMP from ATP; Gαi inhibits some cyclase isoforms. cAMP activates PKA, cyclic nucleotide-gated channels and EPAC. In cells PKA is mostly an inactive tetramer; cAMP binding to its regulatory subunits frees the catalytic subunits, which reach the nucleus and phosphorylate CREB at Ser133. Transcription peaks 30 minutes to 1 hour after cAMP rises, at genes with cAMP response elements (palindrome TGACGTCA or half-sites)Syrovatkina 2016; Taylor 2013; Altarejos and Montminy 2011
Gq / PLCβ / IP3 / DAG / Ca2+ / PKCGαq activates PLCβ1–4, which cleaves PIP2 into soluble IP3 and membrane-bound DAG. IP3 opens the IP3 receptor Ca2+ channel of the endoplasmic reticulum; DAG activates PKC. Conventional PKCs need DAG (C1 domain) and Ca2+ (C2 domain); novel PKCs bind DAG but are not Ca2+-sensitive; atypical PKCs bind neither and are activated by protein scaffoldsSyrovatkina 2016; Newton 2018
NO / cGMPThree NO synthases (nNOS/NOS1, iNOS/NOS2, eNOS/NOS3) make NO and L-citrulline from L-arginine and O2 with electrons from NADPH; nNOS and eNOS depend on Ca2+-calmodulin. NO stimulates soluble guanylyl cyclase, cGMP rises and vascular smooth muscle relaxes. cGMP binds PKG and raises its kinase activity 3- to 10-fold; phosphodiesterases such as PDE5 hydrolyze cGMPCyr 2020; Francis 2010
Kinase relays: RTKs and cytokine receptors reach the nucleus through Ras–ERK, PI3K–AKT–mTOR and JAK–STATSchematic, simplified
Three receptor-to-nucleus kinase pathways: MAPK/ERK; PI3K, AKT and mTOR; JAK/STAT. Arrows activate; flat-ended lines inhibitMAPK/ERK cascadeNucleusGrowth factor (e.g. EGF)RTK dimer, phosphotyrosinesGrb2 adaptorSOS (GDP→GTPexchange)Ras·GDP → Ras·GTPRaf (MAP3K)MEK1/2 (MAPKK)ERK1/2, pThr202/pTyr204Transcription factors, gene expressionPI3K, AKT and mTORGAPInsulin, IGF-1, growth factorsRTK (or GPCR)Class I PI3KPTEN(phosphatase)PIP₂ → PIP₃PDK1 → AKTThr308mTORC2 → AKTSer473AKT (PKB)TSC complex (TSC1, TSC2, TBC1D7)Rheb·GTPmTORC1S6K1 (Thr389)4EBP released fromeIF4EJAK/STATNucleusCytokine (interleukin, interferon)Cytokine receptor dimerJAKs trans-phosphorylate (JAK1, JAK2,JAK3, TYK2)Receptor phosphotyrosines: docking siteSTAT phosphorylated (7 STATs)STAT dimer (SH2–phosphotyrosine)Target-gene promotersOff switches: PIAS, SOCS/CIS, PTPsThree receptor-to-nucleus kinase pathways: MAPK/ERK; PI3K, AKT and mTOR; JAK/STAT. Arrows activate; flat-ended lines inhibitMAPK/ERK cascadeNucleusGrowth factor (e.g. EGF)RTK dimer, phosphotyrosinesGrb2 adaptorSOS (GDP→GTPexchange)Ras·GDP → Ras·GTPRaf (MAP3K)MEK1/2 (MAPKK)ERK1/2, pThr202/pTyr204Transcription factors, gene expressionPI3K, AKT and mTORGAPInsulin, IGF-1, growth factorsRTK (or GPCR)Class I PI3KPTEN (phosphatase)PIP₂ → PIP₃PDK1 → AKT Thr308mTORC2 → AKTSer473AKT (PKB)TSC complex (TSC1, TSC2, TBC1D7)Rheb·GTPmTORC1S6K1 (Thr389)4EBP released fromeIF4EJAK/STATNucleusCytokine (interleukin, interferon)Cytokine receptor dimerJAKs trans-phosphorylate (JAK1, JAK2, JAK3, TYK2)Receptor phosphotyrosines: docking siteSTAT phosphorylated (7 STATs)STAT dimer (SH2–phosphotyrosine)Target-gene promotersOff switches: PIAS, SOCS/CIS, PTPs
Guo YJ, et al. Exp Ther Med 2020;19:1997–2007; Manning BD, Toker A. Cell 2017;169:381–405; Saxton RA, Sabatini DM. Cell 2017;168:960–976; Hu X, et al. Signal Transduct Target Ther 2021;6:402. GAP, GTPase-activating protein.
Text version: MAPK/ERK, PI3K/AKT/mTOR and JAK/STAT
Steps of three kinase pathways
PathwayStepsSource
MAPK / ERKThe adaptor Grb2 binds the activated receptor and recruits SOS to the membrane, where SOS exchanges GDP for GTP on Ras. Ras-GTP activates Raf; Raf activates MEK1/2, dual-specificity kinases that phosphorylate ERK at two regulatory sites, Thr202/185 and Tyr204/187. Active ERK enters the nucleus and regulates transcription factors. ERK1 is 44 kDa, ERK2 42 kDa. ERK1/2 is one of four MAPK cascades, with JNK, p38 and ERK5Guo 2020
PI3K / AKT / mTORRTKs or GPCRs recruit class I PI3K, which makes PIP3; the PIP3 phosphatase PTEN terminates the signal. AKT is fully active when PDK1 phosphorylates Thr308 and mTORC2 phosphorylates Ser473. AKT phosphorylates and inhibits TSC2. The TSC complex (TSC1, TSC2, TBC1D7) is a GAP for Rheb, and Rheb-GTP activates mTORC1, which phosphorylates S6K1 (Thr389) and 4EBP to drive protein synthesisManning and Toker 2017; Saxton and Sabatini 2017
JAK / STATLigand binding brings receptor chains together (some, such as gp130 and the GH receptor, are pre-formed dimers). The JAKs phosphorylate each other and then the receptor, creating docking sites for STATs. JAK phosphorylates the docked STAT, which leaves the receptor, dimerizes through SH2–phosphotyrosine contacts and moves to target-gene promoters. PIAS proteins, SOCS/CIS proteins and protein tyrosine phosphatases switch the pathway offHu 2021
Sensors: AMPK reads cellular energy, NF-κB reads inflammatory signals, and Nrf2 reads oxidants through Keap1Schematic, simplified
Three sensor pathways: AMPK for energy; canonical NF-kappa-B; Nrf2, Keap1 and the antioxidant response element. Arrows activate; flat-ended lines inhibitAMPK, the energy sensorvia RaptorEnergy stress: AMP and ADP rise (bindAMPK-γ)LKB1 complexCaMKKβ (Ca²⁺rise)AMPK αβγ, pThr172: ATP-producingcatabolism on, biosynthesis offTSC2 phosphorylated,activatedmTORC1NF-κB (canonical)Nucleusphosphorylates 2 SerTNF, IL-1, microbial productsTNFR, IL-1R,pattern-recognition receptorsTAK1IKK: IKKα, IKKβ, NEMOIκBα · NF-κB (p50/RelA)IκBα ubiquitylated,degraded in theproteasomep50/RelA freedκB enhancers: target genesNrf2, Keap1 and the ARENucleusUnstressed: 2Keap1 hold Nrf2Oxidants,electrophilesKeap1–Cul3ubiquitylates Nrf2Keap1 cysteinesmodified: Keap1inactiveProteasome: Nrf2half-life ≈10–30 minNrf2 stabilized,enters nucleusNrf2–small Maf binds the ARENQO1, GSTs, GCLC/GCLM, HMOX1, G6PDThree sensor pathways: AMPK for energy; canonical NF-kappa-B; Nrf2, Keap1 and the antioxidant response element. Arrows activate; flat-ended lines inhibitAMPK, the energy sensorvia RaptorEnergy stress: AMP and ADP rise (bind AMPK-γ)LKB1 complexCaMKKβ (Ca²⁺ rise)AMPK αβγ, pThr172: ATP-producing catabolism on,biosynthesis offTSC2 phosphorylated,activatedmTORC1NF-κB (canonical)Nucleusphosphorylates 2 SerTNF, IL-1, microbial productsTNFR, IL-1R, pattern-recognitionreceptorsTAK1IKK: IKKα, IKKβ, NEMOIκBα · NF-κB (p50/RelA)IκBα ubiquitylated,degraded in theproteasomep50/RelA freedκB enhancers: target genesNrf2, Keap1 and the ARENucleusUnstressed: 2 Keap1hold Nrf2Oxidants, electrophilesKeap1–Cul3ubiquitylates Nrf2Keap1 cysteinesmodified: Keap1 inactiveProteasome: Nrf2half-life ≈10–30 minNrf2 stabilized, entersnucleusNrf2–small Maf binds the ARENQO1, GSTs, GCLC/GCLM, HMOX1, G6PD
Hardie DG, Ross FA, Hawley SA. Nat Rev Mol Cell Biol 2012;13:251–262; Saxton and Sabatini 2017; Liu T, et al. Signal Transduct Target Ther 2017;2:17023; Tonelli C, Chio IIC, Tuveson DA. Antioxid Redox Signal 2018;29:1727–1745. Gene names in the last box are the Nrf2 targets named in Tonelli et al.
Text version: AMPK, NF-κB and Nrf2/Keap1/ARE
Steps of three sensor pathways
PathwayStepsSource
AMPKAMPK is an αβγ heterotrimer. Its activity rises more than 100-fold when Thr172 is phosphorylated, mainly by the LKB1 complex or by CaMKKβ after a Ca2+ rise. AMP and ADP binding to the γ subunit promotes that phosphorylation and slows its removal; AMP also activates allosterically, up to about 10-fold. Active AMPK increases ATP-producing catabolism and switches off biosynthesis. It inhibits mTORC1 by phosphorylating and activating TSC2 and by phosphorylating RaptorHardie 2012; Saxton and Sabatini 2017
NF-κB (canonical)The family has five members: p50, p52, RelA (p65), RelB and c-Rel. IκB proteins hold them in the cytoplasm. Cytokine receptors, pattern-recognition receptors and TNF receptors activate the IKK complex (IKKα, IKKβ, NEMO); pattern-recognition receptor pathways converge on TAK1, which activates IKK. IKK phosphorylates IκBα at two N-terminal serines, and IκBα is ubiquitylated and degraded in the proteasome. p50/RelA and p50/c-Rel dimers then enter the nucleus. The noncanonical pathway instead processes p100 to p52 through NIK and IKKαLiu 2017
Nrf2 / Keap1 / AREWithout stress, two Keap1 molecules bind Nrf2 at its ETGE and DLG motifs; Keap1 is the adaptor for the Cul3 E3 ubiquitin ligase, so Nrf2 is continuously ubiquitylated and degraded, with a half-life of about 10–30 min. Oxidation of reactive Keap1 cysteines inactivates Keap1; Nrf2 accumulates, enters the nucleus, pairs with a small Maf protein (MafF, MafG or MafK) and binds the antioxidant response element (ARE). Targets include NQO1, glutathione S-transferases, the GCLC and GCLM subunits of glutamate-cysteine ligase, HMOX1 and G6PDTonelli 2018

Pathways cross-connect: AKT also phosphorylates c-Raf and inhibits it (Manning and Toker 2017), and the AhR, described in the next section, can induce the gene for Nrf2 (Tonelli et al. 2018).

Liver sensors

The liver senses foreign compounds through PXR, CAR and AhR

Three receptors detect drugs, food chemicals and pollutants and respond by making more of the enzymes and transporters that clear them. This is induction. Its effect on another drug's exposure, and the FDA potency categories, are on the ADME page; the enzymes themselves are introduced in its first-pass section.

PXR and CAR pair with RXR and switch on CYP3A4 and CYP2B6; AhR pairs with ARNT and switches on CYP1A2Schematic
Three liver xenobiotic sensors, PXR, CAR and AhR: their activators, their state before activation, the partner they bind DNA with, and the drug-metabolism genes they switch onnucleusActivators (examples)Before activationIn the nucleusGenes switched onPXR (NR1I2)Hyperforin (St John's wort),rifampicin, lovastatinActivated only by ligandbinding; large, flexible ligandpocketPXR–RXR binds responseelementsCYP3A4, CYP2B6, CYP2Cs,UGT1A1, MDR1 (P-gp)CAR (NR1I3)Direct ligands (CITCO) orindirect activatorsHeld in the cytoplasm (Hsp90,CCRP) until activated, inprimary hepatocytesCAR–RXR binds responseelementsCYP2B6, CYP3A4, CYP2Cs,UGT1A1, MDR1 (P-gp)AhRDioxins, PAHs;indole-3-carbinol; quercetin;FICZCytoplasmic complex with 2HSP90, p23, XAP2AhR–ARNT binds xenobioticresponse elementsCYP1A2 (ICH marker); AhRR,its own repressorICH M12 (2024): test in human hepatocytes from ≥ 3 donors; CYP3A4 and CYP2B6 mark PXR/CAR, CYP1A2 marks AhR; induction cannot be excluded at ≥ 2-foldmRNA, concentration-dependent, below 50 × Cmax,u​Three liver xenobiotic sensors, PXR, CAR and AhR, each from activator to the genes it switches onPXR (NR1I2)Hyperforin (St John's wort), rifampicin, lovastatinActivated only by ligand binding; large, flexible ligandpocketPXR–RXR binds response elementsCYP3A4, CYP2B6, CYP2Cs, UGT1A1, MDR1 (P-gp)CAR (NR1I3)Direct ligands (CITCO) or indirect activatorsHeld in the cytoplasm (Hsp90, CCRP) until activated, inprimary hepatocytesCAR–RXR binds response elementsCYP2B6, CYP3A4, CYP2Cs, UGT1A1, MDR1 (P-gp)AhRDioxins, PAHs; indole-3-carbinol; quercetin; FICZCytoplasmic complex with 2 HSP90, p23, XAP2AhR–ARNT binds xenobiotic response elementsCYP1A2 (ICH marker); AhRR, its own repressorICH M12 (2024): human hepatocytes from ≥ 3 donors;markers CYP3A4, CYP2B6 (PXR/CAR) and CYP1A2 (AhR);positive signal: ≥ 2-fold mRNA, concentration-dependent,below 50 × Cmax,u​
Tolson AH, Wang H. Adv Drug Deliv Rev 2010;62:1238–1249; Concise Guide 2025/26: Nuclear hormone receptors (hyperforin, rifampicin and lovastatin listed as PXR agonists; CITCO as a CAR agonist); Larigot L, et al. Biochim Open 2018;7:1–9; ICH M12 Drug Interaction Studies, adopted May 21, 2024, section 2.1.4.

PXR is activated only by ligand binding and has a large, flexible binding pocket, so it responds to many unrelated structures (Tolson and Wang 2010).

Explanation, details and sources

PXR and CAR are NR1I nuclear receptors that form heterodimers with RXR. Neither has an established endogenous physiological agonist, although high concentrations of bile acids and bile pigments activate both (Concise Guide 2025/26). They regulate a largely overlapping set of genes: CYP3A4, CYP2B6, CYP2Cs and CYP2A6; UGT1A1, UGT1A6 and UGT1A9; GSTs and SULTs; and the transporters MDR1 (P-gp), MRPs and OATPs. Most known CAR activators act indirectly, without binding the receptor, and in primary hepatocytes CAR waits in the cytoplasm until activated (Tolson and Wang 2010).

The AhR is a cytoplasmic protein held in a complex with two HSP90 molecules, p23 and XAP2. A ligand that diffuses into the cell binds its PAS B domain; the receptor moves to the nucleus, pairs with ARNT and binds xenobiotic response elements. One target is its own repressor, AhRR. Ligands include dioxins, PCBs and polycyclic aromatic hydrocarbons; dietary flavonoids such as quercetin and resveratrol; indole-3-carbinol from cruciferous vegetables; and tryptophan metabolites such as FICZ. Quercetin and resveratrol are reported to act as both agonists and antagonists (Larigot et al. 2018, review).

ICH M12 framework for in vitro enzyme induction
ICH M12 elementWhat the guideline says
Receptors to considerInduction via PXR, CAR, AhR and, if relevant, other pathways should be evaluated
Test systemHuman hepatocytes from at least 3 individual donors; induction measured at the mRNA level
Marker enzymesAlways CYP3A4 and CYP2B6 (PXR/CAR) and CYP1A2 (AhR); CYP2C8, CYP2C9 and CYP2C19 are induced via PXR but are generally less inducible than CYP3A4
Basic mRNA fold-change criterionInduction cannot be excluded if, in at least one donor, CYP mRNA rises in a concentration-dependent way and reaches ≥ 2-fold at concentrations below 50 × Cmax,u (unbound peak plasma concentration)
Assay sensitivityPositive controls normally raise CYP1A2, CYP2B6 and CYP3A4 mRNA at least 6-fold
Clinical categoriesA strong inducer lowers the AUC of a sensitive index substrate by ≥ 80%, a moderate one by ≥ 50 to < 80%, a weak one by ≥ 20 to < 50%

ICH M12 Guideline, Drug Interaction Studies, final version adopted May 21, 2024: sections 2.1.4, 2.1.4.1 and 7.3.4, and the inducer classification in section 5.3.2. The guideline addresses investigational drugs.

St John's wort shows the mechanism in people. Hyperforin binds PXR with a Ki of 27 nM, and hypericum extract or hyperforin markedly induced CYP3A4 in primary human hepatocytes (Moore et al. 2000, in vitro). Studies in healthy volunteers then measured the enzymes directly.

In healthy volunteers, 14 days of St John's wort raised CYP3A4, P-gp, CYP2B6 and, in women, CYP1A2 measures 1.2- to 2-foldHuman studies, published values
After 14 days of St John's wort extract, eight measures of drug-metabolizing enzymes and P-glycoprotein in healthy volunteers rose 1.2- to 2-fold over baseline; CYP2D6 did not changeno changeAlprazolam clearance (oral probe)CYP3A4Alprazolam clearance (oral probe): 2-fold; Markowitz 2003, 12 adults2×Markowitz 2003, 12 adults6β-OH-cortisol/cortisol in urine, women6β-OH-cortisol/cortisol in urine, women: 1.9-fold (95% CI 1.1–3); Wenk 2004, 8 women1.9×Wenk 2004, 8 women6β-OH-cortisol/cortisol in urine, men6β-OH-cortisol/cortisol in urine, men: 1.5-fold (95% CI 1.3–1.9); Wenk 2004, 8 men1.5×Wenk 2004, 8 menDuodenal CYP3A4 proteinDuodenal CYP3A4 protein: 1.5-fold; Dürr 2000, 8 men1.5×Dürr 2000, 8 menHepatic CYP3A4 activity (erythromycinbreath test)Hepatic CYP3A4 activity (erythromycin breath test): 1.4-fold; Dürr 2000, 8 men1.4×Dürr 2000, 8 menDuodenal P-glycoproteinP-gp (MDR1)Duodenal P-glycoprotein: 1.4-fold; Dürr 2000, 8 men1.4×Dürr 2000, 8 menBupropion oral clearance (130.0 vs 108.3L/h)CYP2B6Bupropion oral clearance (130.0 vs 108.3 L/h): 1.2-fold; Lei 2010, 18 men1.2×Lei 2010, 18 menCaffeine metabolic ratio, women (notsignificant in men)CYP1A2Caffeine metabolic ratio, women (not significant in men): 1.2-fold (95% CI 1.1–1.4); Wenk 2004, 8 women1.2×Wenk 2004, 8 women1×1.5×2×3×Ratio after St John's wort to baseline (log scale)CYP2D6: no significant change in the dextromethorphan ratio (Markowitz 2003); Wenk 2004 concluded CYP2D6 was not affectedAfter 14 days of St John's wort extract, eight measures of drug-metabolizing enzymes and P-glycoprotein in healthy volunteers rose 1.2- to 2-fold over baseline; CYP2D6 did not changeno changeCYP3A4: Alprazolam clearanceAlprazolam clearance (oral probe): 2-fold; Markowitz 2003, 12 adults2×CYP3A4: Urinary cortisol ratio, women6β-OH-cortisol/cortisol in urine, women: 1.9-fold (95% CI 1.1–3); Wenk 2004, 8 women1.9×CYP3A4: Urinary cortisol ratio, men6β-OH-cortisol/cortisol in urine, men: 1.5-fold (95% CI 1.3–1.9); Wenk 2004, 8 men1.5×CYP3A4: Duodenal CYP3A4 proteinDuodenal CYP3A4 protein: 1.5-fold; Dürr 2000, 8 men1.5×CYP3A4: Erythromycin breath testHepatic CYP3A4 activity (erythromycin breath test): 1.4-fold; Dürr 2000, 8 men1.4×P-gp (MDR1): Duodenal P-gp proteinDuodenal P-glycoprotein: 1.4-fold; Dürr 2000, 8 men1.4×CYP2B6: Bupropion clearanceBupropion oral clearance (130.0 vs 108.3 L/h): 1.2-fold; Lei 2010, 18 men1.2×CYP1A2: Caffeine ratio, womenCaffeine metabolic ratio, women (not significant in men): 1.2-fold (95% CI 1.1–1.4); Wenk 2004, 8 women1.2×1×1.5×2×3×Ratio after St John's wort to baseline (log scale)CYP2D6: no significant change in the dextromethorphanratio (Markowitz 2003); Wenk 2004 concluded CYP2D6was not affected
Dürr D, et al. Clin Pharmacol Ther 2000;68:598–604; Markowitz JS, et al. JAMA 2003;290:1500–1504; Wenk M, Todesco L, Krähenbühl S. Br J Clin Pharmacol 2004;57:495–499 (95% CI shown); Lei HP, et al. Xenobiotica 2010;40:275–281 (ratio of mean oral clearances computed on this page). Different probes, products and designs; read each point against its own study.
Show data: St John's wort and enzyme measures in people
Human studies of St John's wort and drug-metabolizing enzymes
StudyParticipants and productMeasureResult
Dürr et al. 20008 healthy men; extract for 14 daysDuodenal P-gp/MDR1 and CYP3A4 protein; erythromycin breath test; digoxinP-gp 1.4-fold, CYP3A4 1.5-fold; hepatic CYP3A4 activity 1.4-fold; digoxin exposure −18%
Markowitz et al. 200312 healthy adults (6 men, 6 women); 300 mg tablet three times a day for 14 daysAlprazolam (CYP3A4); dextromethorphan/dextrorphan in urine (CYP2D6)Alprazolam AUC halved, clearance doubled, half-life 12.4 (SD 3.9) → 6.0 (2.4) h; CYP2D6 ratio 0.006 → 0.014, P =.26
Wenk et al. 20048 men, 8 women; 300 mg extract three times a day for 14 daysUrinary 6β-hydroxycortisol/cortisol (CYP3A4); caffeine metabolite ratios (CYP1A2)CYP3A4 1.5 (95% CI 1.3–1.9) men, 1.9 (1.1–3.0) women; CYP1A2 1.2 (1.1–1.4) in women only; CYP2D6, NAT2 and xanthine oxidase not affected
Lei et al. 201018 healthy Chinese men; 325 mg three times a day for 14 daysBupropion, a CYP2B6 substrateOral clearance 108.3 → 130.0 L/h; AUC0–∞ 1.4 → 1.2 µg·h/mL; half-life unchanged

Values from the published abstracts. Wenk et al. also report dextromethorphan ratios (0.9 in men, 1.9 in women) that their abstract's conclusion does not treat as a CYP2D6 effect; they are not plotted. The midazolam studies of St John's wort and goldenseal, with FDA potency bands, are on the ADME page. Ingredient entries: St. John's wort, Goldenseal.

Diet moves these enzymes too. In a randomized crossover feeding study, 36 non-smoking adults had higher CYP1A2 activity on a brassica-vegetable diet and lower activity on an apiaceous-vegetable diet, measured by caffeine metabolite ratios (Lampe et al. 2000). The study did not test which receptor was responsible.

Lampe JW, et al. Carcinogenesis 2000;21:1157–1162.

Lab to people

For curcumin and quercetin, cell-study concentrations sit above what human blood reaches

A pathway result from cultured cells shows what a compound can do at the concentration tested, in the form tested. In people, polyphenols such as curcumin and quercetin circulate mostly as glucuronide and sulfate conjugates, at concentrations below those at which the cell studies in the figure report effects.

Curcumin and quercetin act in cell studies at 1–100 µmol/L; the human blood levels plotted are below 1 µmol/L or undetectablePublished values
Concentrations at which curcumin and quercetin act in cell and enzyme studies, 1 to 100 micromolar, against concentrations measured in human blood, mostly below 1 micromolar, on a log scale0.1–10 µmol/L: maximum plasma polyphenol concentrations after a polyphenol-rich meal (Kroon et al. 2004)0.1–10 µmol/L: peak plasma range after a polyphenol-rich mealcell or enzyme studyhuman blood (measured)below this limitTNF-α, IL-1β effects, RAW 264.7 macrophagesCurcuminCurcumin: TNF-α, IL-1β effects, RAW 264.7 macrophages, 100 µmol/L100Cytotoxicity IC₅₀, kidney cells and macrophagelineCurcumin: Cytotoxicity IC₅₀, kidney cells and macrophage line, 15.2–31 µmol/L15.2–31Colloid (aggregate) formation in assay bufferCurcumin: Colloid (aggregate) formation in assay buffer, 10–20 µmol/L10–20NF-κB inhibition IC₅₀, A549 cellsCurcumin: NF-κB inhibition IC₅₀, A549 cells, 10–20 µmol/L10–20Free curcumin in serum after 10 or 12 g: 11 of 12people below the limitLOD 0.14Curcumin in serum, 0.5–8 g: none detectedLOD 0.08Cytokine secretion blocked, LPS-stimulatedhuman bloodQuercetinQuercetin: Cytokine secretion blocked, LPS-stimulated human blood, 25 µmol/L25NF-κB signaling IC₅₀Quercetin: NF-κB signaling IC₅₀, 4–11 µmol/L4–11Raf/MEK1/ERK IC₅₀Quercetin: Raf/MEK1/ERK IC₅₀, 1–10 µmol/L1–10JAK3 IC₅₀Quercetin: JAK3 IC₅₀, 2 µmol/L2Plasma quercetin, median Cmax​ after 150 mgQuercetin: Plasma quercetin, median C_{max} after 150 mg, 0.431 µmol/L0.431Four conjugates after onions (275 µmolflavonols), each Cmax​< 1 each0.030.10.3131030100300Concentration, µmol/L (log scale)Concentrations at which curcumin and quercetin act in cell and enzyme studies, 1 to 100 micromolar, against concentrations measured in human blood, mostly below 1 micromolar, on a log scale0.1–10 µmol/L: maximum plasma polyphenol concentrations after a polyphenol-rich meal (Kroon et al. 2004)0.1–10 µmol/L: peak plasma range after a polyphenol-richmealcell or enzyme studyhuman blood (measured)below this limitCurcumin: Cytokine effects, macrophage lineCurcumin: TNF-α, IL-1β effects, RAW 264.7 macrophages, 100 µmol/L100Curcumin: Cytotoxicity IC₅₀ (2 cell lines)Curcumin: Cytotoxicity IC₅₀, kidney cells and macrophage line, 15.2–31 µmol/L15.2–31Curcumin: Aggregation in assay bufferCurcumin: Colloid (aggregate) formation in assay buffer, 10–20 µmol/L10–20Curcumin: NF-κB IC₅₀, A549 cellsCurcumin: NF-κB inhibition IC₅₀, A549 cells, 10–20 µmol/L10–20Curcumin: Serum, 10–12 g: 11 of 12 below LODLOD 0.14Curcumin: Serum, 0.5–8 g: none detectedLOD 0.08Quercetin: Cytokines blocked, human bloodQuercetin: Cytokine secretion blocked, LPS-stimulated human blood, 25 µmol/L25Quercetin: NF-κB IC₅₀Quercetin: NF-κB signaling IC₅₀, 4–11 µmol/L4–11Quercetin: Raf/MEK1/ERK IC₅₀Quercetin: Raf/MEK1/ERK IC₅₀, 1–10 µmol/L1–10Quercetin: JAK3 IC₅₀Quercetin: JAK3 IC₅₀, 2 µmol/L2Quercetin: Plasma, 150 mg: median Cmax​Quercetin: Plasma quercetin, median C_{max} after 150 mg, 0.431 µmol/L0.431Quercetin: Four conjugates after onions, each Cmax​< 1 each0.030.10.3131030100300Concentration, µmol/L (log scale)
Cell and enzyme values: Abdel-Tawab M. Pharmaceuticals 2021;14:437 (review of in vitro IC50 values) and Nelson KM, et al. J Med Chem 2017;60:1620–1637. Human values: Lao CD, et al. BMC Complement Altern Med 2006;6:10; Vareed SK, et al. Cancer Epidemiol Biomarkers Prev 2008;17:1411–1417; Egert S, et al. J Nutr 2008;138:1615–1621; Mullen W, et al. Br J Nutr 2006;96:107–116. Band: Kroon PA, et al. Am J Clin Nutr 2004;80:15–21. Curcumin detection limits converted from µg/mL with molecular weight 368.4 g/mol (PubChem CID 969516).
Show data: concentrations in the figure
Concentrations of curcumin and quercetin in cell studies and in human blood
Compound and settingValue as publishedµmol/LSource
Curcumin, TNF-α and IL-1β effects in RAW 264.7 mouse macrophages100 µM100Abdel-Tawab 2021
Curcumin, cytotoxicity IC50, human kidney cells and murine macrophage line15.2 and 31 µM15.2–31Nelson 2017
Curcumin, critical aggregation concentration in assays10–20 µM, “common compound testing concentrations”10–20Nelson 2017
Curcumin, NF-κB inhibition IC50, TNF-α-stimulated A549 cells10–20 µM10–20Abdel-Tawab 2021
Free curcumin in serum, single doses of 10 or 12 g (12 healthy adults)Detected in 1 subject; detection limit 50 ng/mL. Glucuronide and sulfate conjugates found in allbelow 0.136 in 11 of 12Vareed 2008
Curcumin in serum, single doses of 0.5–8 g (healthy adults)Not detected; detection limit 0.031 µg/mLbelow 0.084Lao 2006
Quercetin, cytokine secretion blocked in LPS-stimulated human whole blood25 µM25Abdel-Tawab 2021
Quercetin, NF-κB signaling IC504–11 µM4–11Abdel-Tawab 2021
Quercetin, Raf/MEK1/ERK IC501–10 µM1–10Abdel-Tawab 2021
Quercetin, JAK3 IC502 µM2Abdel-Tawab 2021
Plasma quercetin, median Cmax after 150 mg quercetin (subgroup of 15)431 nmol/L, at 360 min0.431Egert 2008
Quercetin conjugates in plasma after lightly fried onions with 275 µmol flavonolsSub-micromolar Cmax for each of four conjugates, at 0.6–0.8 hbelow 1 eachMullen 2006
Peak plasma polyphenols after a polyphenol-rich meal0.1–10 µmol/L0.1–10Kroon 2004
  • Activity in a cell assay at 10 µmol/L≠the same activity in a person whose blood holds 0.4 µmol/L
  • The aglycone tested in the dish≠the glucuronide and sulfate conjugates that circulate
  • Activating a pathway in cells≠a demonstrated health effect in people
Explanation, details and sources

Kroon et al. (2004) named two flaws in typical polyphenol cell studies. Cells are treated with aglycones or extracts, although first-pass metabolism means plasma and tissues meet mostly conjugates (green tea catechins are the exception). And concentrations should be of the same order as the peak plasma concentrations reached after a polyphenol-rich meal, 0.1–10 µmol/L. Across 97 human studies, total plasma metabolites ranged from 0 to 4 µmol/L after 50 mg aglycone equivalents (Manach et al. 2005).

Measured forms matter. After onions, Mullen et al. (2006) quantified five flavonol conjugates in plasma and noted that hydrolysis, used in many earlier studies, would have reported only quercetin and isorhamnetin. Vareed et al. (2008) found free curcumin in 1 of 12 subjects, while glucuronide and sulfate conjugates appeared in all; a one-compartment pharmacokinetic model fitted to their serum data estimated a Cmax of 2.30 ± 0.26 µg/mL (mean ± SE) after 10 g for the curcumin glucuronide and sulfate conjugates, not free curcumin. For curcumin bioavailability formulations and what their studies measured, see the ADME page.

Assay artifacts add a second gap. Nelson et al. (2017) describe curcumin as unstable, chemically reactive and aggregating, note reports that label it a pan-assay interference compound (PAINS), and give a critical aggregation concentration of 10–20 µM that matches common testing concentrations; detergent raised its apparent IC50 against three enzymes. Their review concludes that no form of curcumin or its close analogues has the properties of a good drug candidate. For AMPK, Hardie et al. (2012) list resveratrol, EGCG, capsaicin, curcumin, garlic and berberine among plant products that switch AMPK on in cells; most act in intact cells but not in cell-free assays, and resveratrol, like metformin, does so indirectly, usually by inhibiting mitochondrial ATP synthesis.

Kroon PA, et al. Am J Clin Nutr 2004;80:15–21; Manach C, et al. Am J Clin Nutr 2005;81(1 Suppl):230S–242S; Mullen W, Edwards CA, Crozier A. Br J Nutr 2006;96:107–116; Vareed SK, et al. 2008; Nelson KM, et al. 2017; Hardie DG, et al. 2012. Ingredient entries: Turmeric, Quercetin, Resveratrol, Berberine, Green tea.

EUTECNIQ Proposed

Where EUTECNIQ would use this

EUTECNIQ would test botanical constituents at concentrations matched to measured human exposure, include the circulating conjugates, and screen extracts for PXR, CAR and AhR-driven induction using the ICH M12 markers before any human study. None of this exists yet.

Related pages: ADME, PK and PBPK · Bioactive compounds · Bioavailability design

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.